StockNow
Log in
Global Markets

GSK (GSK LN) discontinues camlipixant development in refractory chronic cough after CALM-2 did not reach statistical significance in the primary endpoint

StockNow breaking-news AI analysis

GSK discontinued camlipixant after CALM-2 trial failed its primary endpoint. However, its broader respiratory and infectious disease pipeline remains strong with depemokimab and bepirovirsen reaching key regulatory milestones.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)